The latest developments across the GLP-1 landscape, from new drug approvals and clinical research to pricing changes and policy shifts. Stay informed on the updates that affect Ozempic, Wegovy, Mounjaro, and the wider category.
News & Updates
Retatrutide, a new triple-hormone drug, showed striking weight loss results in early clinical trials. Here's what those numbers mean for patients, how it stacks up against existing GLP-1 medications, and what you should realistically expect if it eventually reaches the market.
Generic semaglutide, the active ingredient in Ozempic, is set to arrive at Canadian pharmacies this week at a significantly lower price than the brand-name version. This is a major development for patients managing type 2 diabetes and weight loss. Here is what Canadian patients and US readers watching this space should know.
Maryland's Drug Affordability Board has placed payment limits on Ozempic (semaglutide), marking one of the first state-level price caps on a major GLP-1 medication. This article breaks down what the decision means for patients, how it could affect your costs, and what to do if you live outside Maryland.
Medicare is implementing a $50 per month out-of-pocket cap on GLP-1 medications for eligible beneficiaries, offering significant savings for patients who use drugs like semaglutide or tirzepatide. This guide breaks down who qualifies, how the bridge program works, and what steps you should take right now.
Maryland has become one of the first states to set a price cap on Ozempic through its prescription drug affordability board. This move could reshape how GLP-1 medications are priced across the country, and it matters whether you're currently on semaglutide or considering starting it.
Research confirms that people taking GLP-1 medications like semaglutide and tirzepatide face a specific and frustrating form of social stigma. This article breaks down what the science shows, why this stigma exists, and practical ways to protect your mental health and stay committed to your treatment plan.
Social media is flooded with "natural Mounjaro" drink recipes claiming to mimic the weight loss effects of tirzepatide. Before you blend anything, here's what the science says about these viral concoctions, why they fall short, and what your real options look like.
Eli Lilly is advancing a new oral weight loss drug that may deliver stronger results than both Wegovy and its own Zepbound. Here's what the clinical data shows so far, what it means for patients currently on GLP-1 medications, and how to think about your options while this drug moves through trials.
